Media ReleasesRadiopharm Theranostics

View All Radiopharm Theranostics News

Radiopharm Theranostics secures Share Facility Agreement of up to A$12.5m

-- Up to A$12.5 million investment by US institutional investor, Lind Partners.
-- Under a Share Subscription Agreement, RAD will receive A$1.2 million, with up to a further A$11.3 million in funding available under a Share Purchase Agreement (although RAD’s ability to receive the full amount will be subject to shareholder approval).
-- The Share Purchase Agreement is a staged private placement of up to $11.3 million in monthly instalments of between A$50,000 and up to A$1 million monthly over a 12-month period (unless extended), with an initial instalment of A$300,000.
-- Funds raised will support the clinical trial pipeline and otherwise for general working capital of the Company. Funds relating to the A$1.5 million initial investments are expected to be received within five business days.

Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company) a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce a Share Subscription Agreement and a Share Purchase Agreement (together the Agreements) to provide initial funding of A$1.5 million and total funding of up to A$12.5 million with Lind Global Fund II, LP an entity managed by New York-based The Lind Partners (together, Lind). Lind invests in small and mid-cap companies publicly traded in the US, Canada, Australia and the UK.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?